PYC Therapeutics Ltd
PYC
Company Profile
Business description
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company’s drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
Contact
6 Verdun Street
Harry Perkins Institute of Medical Research
Nedlands
PerthWA6009
AUST: +61 861510992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
Fears of deteriorating loan quality sends bank share plummeting
stocks
Why it’s not all bad news for Flight Centre following downgrade
Despite an earnings downgrade, shares in FLT remain undervalued.
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,947.90 | 17.50 | -0.20% |
| CAC 40 | 8,431.61 | 46.12 | 0.55% |
| DAX 40 | 24,994.83 | 254.47 | 1.03% |
| Dow JONES (US) | 51,920.62 | 71.72 | 0.14% |
| FTSE 100 | 10,529.89 | 68.26 | 0.65% |
| HKSE | 22,644.49 | 432.42 | -1.87% |
| NASDAQ | 25,358.60 | 118.03 | -0.46% |
| Nikkei 225 | 68,799.65 | 3,566.70 | -4.93% |
| NZX 50 Index | 13,481.57 | 11.48 | -0.09% |
| S&P 500 | 7,357.49 | 0.73 | -0.01% |
| S&P/ASX 200 | 8,749.10 | 14.90 | -0.17% |
| SSE Composite Index | 4,032.30 | 87.98 | -2.14% |